Organon & Co. (OGN)

$13.34 +0.03 (0.23%)
Market Cap 3.50B
Revenue (ttm) 6.22B
Net Income (ttm) 187.00M
EPS (ttm) N/A
PE Ratio 4.25
Forward PE 4.14
Profit Margin 3.01%
Debt to Equity Ratio 9.49
Volume 2,649,546
Avg Vol 10,065,204
Day's Range N/A - N/A
Shares Out 262.60M
Stochastic %K 32%
Beta 1.57
Analysts Hold
Price Target $10.50

Company Profile

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregna...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 551 430 6900
Address:
30 Hudson Street, Floor 33, Jersey City, United States
LongMoneyMovements
LongMoneyMovements May. 13 at 5:26 PM
$SLS $OGN
0 · Reply
BiotechJedi1728
BiotechJedi1728 May. 12 at 11:22 PM
$DARE This will likely be approved and someone will swoop in. Maybe the company that bought $OGN will want another women’s health asset. https://www.linkedin.com/posts/positive-interim-phase-3-results-highlight-share-7460079253968117760-MKDN?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAACdVpABt6kGksglM6yOtoqYXdcE9HE9y_M&utm_campaign=share_via
0 · Reply
Newmoves
Newmoves May. 7 at 9:59 PM
$OGN what is the possibility this acquisition falls through?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 2:20 AM
$OGN RSI: 79.53, MACD: 1.6825 Vol: 2.50, MA20: 10.00, MA50: 7.92 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
InvestingSpaceman
InvestingSpaceman May. 4 at 8:57 PM
$ROLR $BE $OGN $XRX /\\/
0 · Reply
Jackprong
Jackprong May. 4 at 3:39 PM
$OGN I’m out! Made my gains by buying this issue at lower sp and the buyout. Food stocks and REITs will be the ones I accumulate going forward.
1 · Reply
OnlyFibs
OnlyFibs May. 2 at 8:17 PM
$OGN 40% since alerted and more to come, folks..
0 · Reply
TalkMarkets
TalkMarkets May. 1 at 6:06 PM
An April To Remember For Stocks $OGN $INTC $SPY $QQQ $DIA https://talkmarkets.com/article/an-april-to-remember-for-stocks-1777658779
0 · Reply
Alphasearch
Alphasearch May. 1 at 3:48 PM
$OGN Sold all of my shares for a loss. Not worth waiting a year holding for .75 more and risk of the deal not going through. Could get a competing bid, but with $8 billion of debt and inept criminal execs not worth the risk. Better fish to fry in a bull market
0 · Reply
yohouoho
yohouoho May. 1 at 1:23 AM
$OGN PURE UNADULTERATED DOG SHIT.
1 · Reply
Latest News on OGN
Organon will not provide financial guidance due to pending merger

2026-04-30T12:10:58.000Z - 13 days ago

Organon will not provide financial guidance due to pending merger

Organon Reports Results for the First Quarter Ended March 31, 2026

Apr 30, 2026, 7:30 AM EDT - 13 days ago

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon cancels Q1 earnings call

2026-04-29T12:37:38.000Z - 14 days ago

Organon cancels Q1 earnings call

Organon Cancels First Quarter Earnings Call

Apr 29, 2026, 7:30 AM EDT - 14 days ago

Organon Cancels First Quarter Earnings Call

Organon gets European Commission marketing authorization for Poherdy

2026-04-29T09:50:39.000Z - 14 days ago

Organon gets European Commission marketing authorization for Poherdy

Organon moved to No Rating at BofA

2026-04-28T12:11:19.000Z - 15 days ago

Organon moved to No Rating at BofA

Organon downgraded to Neutral from Outperform at BNP Paribas

2026-04-28T11:41:54.000Z - 15 days ago

Organon downgraded to Neutral from Outperform at BNP Paribas

Organon upgraded to Neutral from Underweight at Piper Sandler

2026-04-27T20:45:26.000Z - 15 days ago

Organon upgraded to Neutral from Underweight at Piper Sandler

Organon rises 17.0%

2026-04-27T16:08:08.000Z - 16 days ago

Organon rises 17.0%

Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical

Apr 27, 2026, 11:02 AM EDT - 16 days ago

Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical

Organon rises 17.2%

2026-04-27T14:34:23.000Z - 16 days ago

Organon rises 17.2%

Unusually active option classes on open April 27th

2026-04-27T13:52:53.000Z - 16 days ago

Unusually active option classes on open April 27th

CLF INFY JOBY QCOM QGEN SRAD USAS

Organon Stock Soars After Sun Seals Takeover. Why Pharma M&A Is a Hot Play.

Apr 27, 2026, 5:22 AM EDT - 16 days ago

Organon Stock Soars After Sun Seals Takeover. Why Pharma M&A Is a Hot Play.

Why is Sun Pharma betting $11.75B on a struggling US drugmaker?

Apr 27, 2026, 12:19 AM EDT - 16 days ago

Why is Sun Pharma betting $11.75B on a struggling US drugmaker?

Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal

Apr 26, 2026, 10:13 PM EDT - 16 days ago

Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

Apr 26, 2026, 9:16 PM EDT - 16 days ago

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

Sun Pharma to acquire Organon for $14 per share in all-cash transaction

2026-04-27T00:05:07.000Z - 16 days ago

Sun Pharma to acquire Organon for $14 per share in all-cash transaction

Sun Pharma to acquire Organon in $11.75 bln all-cash deal

Apr 26, 2026, 8:01 PM EDT - 16 days ago

Sun Pharma to acquire Organon in $11.75 bln all-cash deal

Sun Pharma signs Definitive Agreement to Acquire Organon

Apr 26, 2026, 7:51 PM EDT - 16 days ago

Sun Pharma signs Definitive Agreement to Acquire Organon

Organon Stock (OGN) Surges on Reports of a $13B Bid

2026-04-25T01:38:00.000Z - 18 days ago

Organon Stock (OGN) Surges on Reports of a $13B Bid

MRK

Organon rises 25.8%

2026-04-24T16:07:27.000Z - 19 days ago

Organon rises 25.8%

Organon rises 22.8%

2026-04-24T14:07:05.000Z - 19 days ago

Organon rises 22.8%

Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026

Apr 16, 2026, 7:30 AM EDT - 27 days ago

Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis

Apr 15, 2026, 7:30 AM EDT - 4 weeks ago

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring.

Apr 10, 2026, 10:01 AM EDT - 4 weeks ago

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring.

This Women's Healthcare Stock Is Up 15% on Reports of a Takeover In the Works

Apr 10, 2026, 9:42 AM EDT - 4 weeks ago

This Women's Healthcare Stock Is Up 15% on Reports of a Takeover In the Works

These Stocks Are Today's Movers: Nvidia, Intel, Lumentum, Coherent, Organon, and More.

Apr 10, 2026, 6:26 AM EDT - 4 weeks ago

These Stocks Are Today's Movers: Nvidia, Intel, Lumentum, Coherent, Organon, and More.

INTC LITE NVDA

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

Mar 27, 2026, 8:00 AM EDT - 6 weeks ago

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 7 weeks ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

ABBV AMRX NVS

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS

Mar 3, 2026, 4:49 AM EST - 2 months ago

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS

New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

Feb 27, 2026, 8:00 AM EST - 2 months ago

New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

Feb 23, 2026, 7:30 AM EST - 2 months ago

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

Organon & Co. Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:30 AM EST - 3 months ago

Organon & Co. Earnings Call Transcript: Q4 2025

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

Feb 12, 2026, 7:30 AM EST - 3 months ago

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

Jan 29, 2026, 7:30 AM EST - 3 months ago

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

Organon Completes Divestiture of JADA® System to Laborie

Jan 28, 2026, 12:45 PM EST - 3 months ago

Organon Completes Divestiture of JADA® System to Laborie

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Jan 16, 2026, 9:12 PM EST - 4 months ago

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Jan 8, 2026, 1:30 AM EST - 4 months ago

Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Organon & Co. Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 10:00 AM EST - 5 months ago

Organon & Co. Transcript: Piper Sandler 37th Annual Healthcare Conference

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 6 months ago

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Nov 17, 2025, 5:30 AM EST - 6 months ago

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Organon & Co. Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:30 AM EST - 6 months ago

Organon & Co. Earnings Call Transcript: Q3 2025

Organon Reports Results for the Third Quarter Ended September 30, 2025

Nov 10, 2025, 7:30 AM EST - 6 months ago

Organon Reports Results for the Third Quarter Ended September 30, 2025

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Nov 7, 2025, 7:30 AM EST - 6 months ago

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

Nov 6, 2025, 7:30 AM EST - 6 months ago

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Oct 27, 2025, 7:44 AM EDT - 7 months ago

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Oct 27, 2025, 7:30 AM EDT - 7 months ago

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 19, 2025, 6:00 AM EDT - 8 months ago

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 2, 2025, 5:30 AM EDT - 9 months ago

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Organon & Co. Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 10 months ago

Organon & Co. Earnings Call Transcript: Q2 2025

Organon Reports Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 7:30 AM EDT - 10 months ago

Organon Reports Results for the Second Quarter Ended June 30, 2025

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

Jul 22, 2025, 7:30 AM EDT - 10 months ago

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

Jul 21, 2025, 4:02 PM EDT - 10 months ago

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Jul 10, 2025, 8:18 AM EDT - 10 months ago

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

Jul 8, 2025, 1:14 PM EDT - 11 months ago

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

VICI

LongMoneyMovements
LongMoneyMovements May. 13 at 5:26 PM
$SLS $OGN
0 · Reply
BiotechJedi1728
BiotechJedi1728 May. 12 at 11:22 PM
$DARE This will likely be approved and someone will swoop in. Maybe the company that bought $OGN will want another women’s health asset. https://www.linkedin.com/posts/positive-interim-phase-3-results-highlight-share-7460079253968117760-MKDN?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAACdVpABt6kGksglM6yOtoqYXdcE9HE9y_M&utm_campaign=share_via
0 · Reply
Newmoves
Newmoves May. 7 at 9:59 PM
$OGN what is the possibility this acquisition falls through?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 2:20 AM
$OGN RSI: 79.53, MACD: 1.6825 Vol: 2.50, MA20: 10.00, MA50: 7.92 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
InvestingSpaceman
InvestingSpaceman May. 4 at 8:57 PM
$ROLR $BE $OGN $XRX /\\/
0 · Reply
Jackprong
Jackprong May. 4 at 3:39 PM
$OGN I’m out! Made my gains by buying this issue at lower sp and the buyout. Food stocks and REITs will be the ones I accumulate going forward.
1 · Reply
OnlyFibs
OnlyFibs May. 2 at 8:17 PM
$OGN 40% since alerted and more to come, folks..
0 · Reply
TalkMarkets
TalkMarkets May. 1 at 6:06 PM
An April To Remember For Stocks $OGN $INTC $SPY $QQQ $DIA https://talkmarkets.com/article/an-april-to-remember-for-stocks-1777658779
0 · Reply
Alphasearch
Alphasearch May. 1 at 3:48 PM
$OGN Sold all of my shares for a loss. Not worth waiting a year holding for .75 more and risk of the deal not going through. Could get a competing bid, but with $8 billion of debt and inept criminal execs not worth the risk. Better fish to fry in a bull market
0 · Reply
yohouoho
yohouoho May. 1 at 1:23 AM
$OGN PURE UNADULTERATED DOG SHIT.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 30 at 11:55 AM
$OGN Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.56 up 64.71% YoY • Reported revenue of $1.46B down -3.50% YoY
0 · Reply
Sir_White
Sir_White Apr. 29 at 3:28 PM
$OGN Sold. Not going to wait for a year to get 14. Thanks Organon & Sun Pharma.
0 · Reply
TeresaTrades
TeresaTrades Apr. 29 at 2:15 PM
Largest CALL OI Decreases $MARA $OGN $CTRA $NUAI $WULF
0 · Reply
briefingcom
briefingcom Apr. 29 at 12:20 PM
$OGN: Organon receives EU approval for first pertuzumab biosimilar https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260429053902OGN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
TristaHarper
TristaHarper Apr. 29 at 9:53 AM
$OGN European Commission (EC) approved Henlius / Organon’s POHERDY® (pertuzumab) First biosimilar to PERJETA approved in the European market Key points: • First Perjeta biosimilar approved in the EU • Expanding competition in oncology biologics • Continued progress in Organon biosimilars pipeline
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 29 at 2:25 AM
Why Did NOK, OGN, XE Stocks Hit 52-Week Highs Today? $NOK $OGN $XE https://stocktwits.com/news/equity/markets/why-did-nok-ogn-xe-stocks-hit-52-week-highs-today/cZBqnmTRe32
0 · Reply
jdlman
jdlman Apr. 28 at 10:53 PM
$OGN cramer says NO
0 · Reply
MrNotSoNice
MrNotSoNice Apr. 28 at 8:40 PM
$OGN Is there and upside left here? Are we maxed out at $14 because of the Sun deal? Time to sell my long? Opinions please. 🤔
1 · Reply
topstockalerts
topstockalerts Apr. 28 at 8:00 PM
$OGN this just turned the corner real quick… you seeing this?
0 · Reply
RunnerSignals
RunnerSignals Apr. 28 at 5:55 PM
Top Stocks Hitting 52-Week High $KOPN $OGN $BTE $BEN $PTEN
0 · Reply